The University of Western Australia

Clin/A/Prof John Walsh

Clinical Associate Professor
Clinical and Adjunct Staff (Medicine and Pharmacology, SCGH)

Contact details

Address

Clinical and Adjunct Staff (Medicine and Pharmacology, SCGH)
The University of Western Australia (M503)
35 Stirling Highway
CRAWLEY WA 6009
Australia

Phone

9346 2466

Fax

9346 3221

Email

John.Walsh@health.wa.gov.au

Biography

Clinical Associate Professor, School of Medicine and Pharmacology, University of Western Australia May 2005 to date
Consultant Endocrinologist, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, August 1999 to date

Key research

1. Thyroid disease: thyroid replacement therapy, epidemiology and genetics of thyroid disease and patterns of care of patients with thyroid disorders.

2. Paget’s disease of bone: molecular genetics, pathogenesis and treatment.

Publications

Selected recent publications:
1.Bhagat MC, Dhaliwal SS, Bonnema SJ, Hegedüs L, Walsh JP. Differences between endocrine surgeons and endocrinologists in the management of nontoxic multinodular goitre. British Journal of Surgery, 2003; 90: 1103-1112. {Impact Factor 3.580}
2.Walsh JP, Shiels L, Lim EM, Bhagat CI, Ward LC, Stuckey BGA, Dhaliwal SS, Chew GT, Bhagat MC, Cussons AJ. Combined thyroxine/liothyronine treatment does not improve wellbeing, quality of life or cognitive function compared to thyroxine alone: A randomized controlled trial in patients with primary hypothyroidism. Journal of Clinical Endocrinology and Metabolism, 2003; 88: 4543-4550. {Impact Factor 5.778}
3.Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BGA, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget’s disease of bone. Bone 2004; 34: 747-754. {Impact Factor 3.530}
4.Hocking LJ, Lucas GJA, Daroszewska A, Cundy T, Nicholson GC, Donath J, Walsh JP, Finlayson C, Cavey JR, Ciani B, Sheppard PW, Searle MS, Layfield R, Ralston SH. UBA domain mutations of SQSTM1 in Paget’s disease of bone: genotype phenotype correlation, functional analysis and structural consequences. Journal of Bone and Mineral Research 2004; 19:1122-1127. {Impact Factor 5.436}
5.Walsh JP. Paget’s disease of bone. Medical Journal of Australia 2004; 181: 262-265. {Impact Factor 2.000}
6.Lucas GJA, Hocking LJ, Daroszewska A, Cundy T, Nicholson GC, Walsh JP, Fraser WD, Meier C, Hooper M, Ralston SH. UBA domain mutations of SQSTM1 in Paget’s disease of bone: Evidence for a founder effect in patients of British descent. Journal of Bone and Mineral Research 2005; 20: 227-231. {Impact Factor 6.527}
7.Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, Michelangeli V. Parity and the risk of autoimmune thyroid disease: a community-based study. Journal of Clinical Endocrinology and Metabolism 2005; 90: 5309-5312. {Impact Factor 6.020}
8.Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, Michelangeli V. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Archives of Internal Medicine 2005; 165:2467-2472. {Impact Factor 8.016}
9.Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, Michelangeli V. Thyroid dysfunction and serum lipids: a community based study. Clinical Endocrinology 2005; 63: 670-675. {Impact Factor 3.412}
10.Lucas GJA, Mehta SG, Hocking LJ, Stewart TL, Cundy T, Nicholson GC, Walsh JP, Fraser WD, Watts GDJ, Ralston SH, Kimonis VE. Evaluation of the role of valosin-containing protein in the pathogenesis of familial and sporadic Paget’s disease of bone. Bone 2006; 38: 280-285 {Impact Factor 3.829}
11.O’Leary P, Feddema PH, Michelangeli VP, Leedman PJ, Chew GT, M Knuiman, Kaye J, Walsh JP. Investigations of thyroid function based on a community health survey: the Busselton thyroid study. Clinical Endocrinology 2006; 64:97-104. {Impact Factor 3.358}.
12.Li M, Eastman CJ, Waite KV, Ma G, Zacharin MR, Topliss DJ, Harding PE, Walsh JP, Ward LC, Mortimer RH, Mackenzie EJ, Byth K, Doyle Z. Are Australian children iodine deficient? Results of the Australian National Iodine Nutrition Study. Medical Journal of Australia 2006; 184:165-169. {Impact Factor 2.582}
13.Ward BK, Magno AL, Blitvich BJ, Rea AJ, Stuckey BGA, Walsh JP, Ratajczak T. Novel mutations in the calcium-sensing receptor gene associated with biochemical and functional differences in familial hypocalciuric hypercalcaemia. Clinical Endocrinology, 2006; 64: 580-587. {Impact Factor 3.358}
14.Rea SL, Walsh JP, Ward L, Yip KH, Ward BK, Kent GN, Steer JH, Xu J, Ratajczak T. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kB signalling and Paget's disease of bone with a severe phenotype. Journal of Bone and Mineral Research 2006; 21: 1136-1145. {Impact Factor 6.635}
15.Walsh JP, Ward LC, Burke V, Bhagat CI, Shiels S, Henley D, Gillett MJ, Gilbert R, Tanner M, Stuckey BGA. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being or quality of life: results of a double blind, randomized clinical trial. Journal of Clinical Endocrinology and Metabolism 2006; 91: 2624-2630. {Impact Factor 5.799}
16.Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, Michelangeli V. Subclinical thyroid dysfunction and blood pressure: a community based study. Clinical Endocrinology 2006; 65: 486-491. {Impact Factor 3.358}.
17.Stuckey BGA, Walsh JP, Ching HL, Stuckey AW, Palmer NR, Thompson PL, Watts GF. Erectile dysfunction predicts generalised cardiovascular disease: evidence from a case-control study. Atherosclerosis 2007; 194: 458-464. {Impact Factor 3.777}
18.Walsh JP, Ryan SA, Lisewski D, Alhamoudi MZ, Brown S, Bennedbæk FN, Hegedüs L. Differences between endocrinologists and endocrine surgeons in management of the solitary thyroid nodule. Clinical Endocrinology 2007; 66: 844-854. {Impact Factor 3.412}
19.Lucas GJA, Riches PL, Hocking LJ, Cundy T, Nicholson GC, Walsh JP, Ralston SH. Identification of a major locus for Paget disease on chromosome 10p13 in families of British descent. Journal of Bone and Mineral Research, 2008; 23: 58-63. {Impact Factor 6.635}
20.Panicker V, Wilson SG, Spector TD, Brown SJ, Falchi M, Richards JB, Surdulescu GL, Lim EM, Fletcher SJ, Walsh JP. Heritability of serum TSH, free T4 and free T3 concentrations: A study of a large UK twin cohort. Clinical Endocrinology 2008; 68: 652-659. {Impact Factor 3.358}
21.Makepeace AE, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, Michelangeli V, Walsh JP. Significant inverse relationship between serum free T4 concentration and body mass index in euthyroid subjects: differences between smokers and non-smokers. Clinical Endocrinology 2008; 69: 648-652. {Impact Factor 3.358}
22.Walsh JP, Attewell R, Stuckey BGA, Hooper MJ, Wark JD, Fletcher S, Ferrari V, Eisman JA. Treatment of Paget's disease of bone: a survey of clinical practice in Australia. Bone 2008; 42: 1219-1225 {Impact Factor 3.829}
23.Gilbert RM, Hadlow NC, Walsh JP, Fletcher SJ, Stuckey BGA, Lim EM. Assessment of thyroid function during pregnancy: first-trimester (weeks 9–13) reference intervals derived from Western Australian women. Medical Journal of Australia 2008; 189:250-253. {Impact Factor 2.582}
24.Panicker V, Wilson SG, Spector TD, Brown SJ, Kato BS, Reed PW, Falchi M, Richards JB, Surdulescu GL, Lim EM Fletcher SJ, Walsh JP. Genetic loci linked to pituitary-thyroid axis setpoints: A genome-wide scan of a large twin cohort. Journal of Clinical Endocrinology and Metabolism, 2008; 93:3519-3523. {Impact Factor 5.799}
25.Rea SL, Walsh JP, Ward L, Magno AL, Ward BK, Shaw B, Layfield R, Kent GN, Xu J, Ratajczak T. Sequestosome 1 mutations in Paget’s disease of bone in Australia: prevalence, genotype/phenotype correlation and a novel non-UBA domain mutation (P364S) associated with increased NF-қB signaling without loss of ubiquitin-binding. Journal of Bone and Mineral Research, in press (accepted 23 January 2009){Impact Factor 6.635}
26.Ang E, Pavlos NJ, Rea SL, Qi M, Chai TL, Walsh JP, Ratajczak T, Zheng MH, Xu J. Proteasome inhibitors impair RANK-induced NF-κB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD and IκBα signaling cascades. Journal of Cellular Physiology, in press (accepted 6 March 2009). {Impact Factor 3.643}

Current external positions

Consultant Endocrinologist, Sir Charles Gairdner Hospital

Current projects

Epidemiology of thyroid disease in the Busselton Health Study
Molecular Genetics of Paget's disease of bone

Research profile

Research profile and publications